Urba S.RUEY-LONG HONGHossain A.M.Cheng R.Orlando M.2021-03-092021-03-0920131743-7555https://www.scopus.com/inward/record.uri?eid=2-s2.0-84888063506&doi=10.1111%2fajco.12060&partnerID=40&md5=4a6fe5db1e181ce9ba35e55731f4c76dhttps://scholars.lib.ntu.edu.tw/handle/123456789/551237Aim: An exploratory subgroup analysis of East Asian (EA) patients in a phase III trial was conducted to assess efficacy and safety trends based on ethnicity. MethodsCisplatin; Clinical trial; Head and neck neoplasm; Pemetrexed; Phase III[SDGs]SDG3cisplatin; pemetrexed; placebo; antineoplastic agent; cisplatin; glutamic acid derivative; guanine; pemetrexed; adult; aged; anemia; anorexia; article; cancer prognosis; China; combination chemotherapy; controlled study; diarrhea; double blind procedure; drug efficacy; drug safety; drug withdrawal; ethnicity; fatigue; febrile neutropenia; female; head and neck squamous cell carcinoma; human; kidney failure; Korea; leukopenia; major clinical study; male; metastasis; monotherapy; multiple cycle treatment; nausea and vomiting; neutropenia; overall survival; phase 3 clinical trial; priority journal; progression free survival; randomized controlled trial; recurrent cancer; Taiwan; thrombocytopenia; treatment response; analogs and derivatives; Asian continental ancestry group; Carcinoma, Squamous Cell; clinical trial; ethnology; Head and Neck Neoplasms; middle aged; Neoplasm Recurrence, Local; survival; treatment outcome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian Continental Ancestry Group; Carcinoma, Squamous Cell; Cisplatin; Double-Blind Method; Female; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcomejournal article10.1111/ajco.12060234420472-s2.0-84888063506